Wyeth said the restructuring of its U.S. sales force was only a start and that it is considering making similar changes globally.
“Obviously it is a first step. We’re also looking internationally. Our European affiliates have started to look at how to optimize the sales force,” Bernard Poussot, head of Wyeth’s pharmaceutical operations, said in a Financial Times report.
Last month Wyeth said it would use inside, part-time sales representatives in the U.S. to complement its full-time sales force, which is being reduced by about 25% to 30%.
Adding the part-timers will result in a net sales-force reduction of about 15%, Poussot said. Wyeth has deployed part-timers in its consumer division for the past few years.
As reported in MM&M (July 2005), the drug maker began piloting part-timers in its pharmaceuticals division in July and said it will fully implement them by year’s end.
Wyeth mulls restructuring its global sales force
Wyeth said the restructuring of its U.S. sales force was only a start and that it is considering making similar changes globally.